Filtros de búsqueda

Lista de obras de Paolo Antonio Ascierto

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond

artículo científico publicado en 2015

3-year treatment with recombinant interferon-alpha as adjuvant therapy of cutaneous malignant melanoma.

artículo científico publicado en 1999

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

artículo científico publicado en 2015

A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results

artículo científico publicado en 2021

A Serum Protein Signature Associated with Outcome After Anti-PD1 Therapy in Metastatic Melanoma.

artículo científico publicado en 2017

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

scientific article published on 06 January 2021

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

artículo científico publicado en 2019

A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy

artículo científico publicado en 2017

A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: potential applications in autoimmunity and cancer.

artículo científico publicado en 2014

A phase 1b/2 study of the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib in patients with BRAF V600E/K-mutant solid tumors

scientific article published on 15 July 2020

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

scientific article published on 03 September 2019

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma.

artículo científico publicado en 2015

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

artículo científico publicado en 2014

Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma

artículo científico publicado en 2016

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

scientific article published on 02 April 2019

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

artículo científico publicado en 2015

Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies.

artículo científico publicado en 2013

Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition.

artículo científico publicado en 2014

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

artículo científico publicado en 2017

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

artículo científico publicado en 2018

Adjuvant Therapy in Resected Melanoma

artículo científico publicado en 2018

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial

artículo científico publicado en 2013

Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review

artículo científico

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

artículo científico

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

scientific article published on 07 August 2019

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

scientific article published on 01 December 2018

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

artículo científico publicado en 2020

Adjuvant therapy of melanoma with interferon: lessons of the past decade

artículo científico publicado en 2008

Adjuvant treatment of malignant melanoma: where are we?

artículo científico publicado en 2005

Adjuvant treatment of melanoma using placebo or no therapies as control-arm: is it ethically correct?

artículo científico publicado en 1999

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

artículo científico publicado en 2018

Advances in immunotherapy for melanoma

scientific article published on 01 August 2014

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology

scientific article published on 21 March 2019

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

scientific article published on 19 August 2019

An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival

artículo científico publicado en 2020

An assessment of factors related to tumor thickness and delay in diagnosis of melanoma in southern Italy

artículo científico publicado en 2002

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

artículo científico publicado en 2018

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients.

artículo científico publicado en 2015

Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases.

artículo científico publicado en 2005

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-r

scientific article published on 04 February 2020

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

artículo científico publicado en 2011

Anti-IL6R role in treatment of COVID-19-related ARDS

scientific article published on 14 April 2020

Anti-PD-1 and PD-L1 antibodies in metastatic melanoma

artículo científico publicado en 2017

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

article

Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma.

artículo científico publicado en 2015

Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma

artículo científico publicado en 2016

Are there, or shall we discover, biomarkers to guide PD-1 inhibition?

artículo científico publicado en 2016

Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?

artículo científico publicado en 2017

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy

artículo científico publicado en 2015

Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases

artículo científico publicado en 2003

Assessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma.

artículo científico publicado en 2014

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study

scientific article published on 01 December 2018

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

scientific article published on 02 January 2020

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials

artículo científico publicado en 2020

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.

artículo científico publicado en 2017

Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study

artículo científico publicado en 2013

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.

artículo científico publicado en 2017

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2020

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

artículo científico publicado en 2014

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma

scientific article published on 15 May 2019

BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas

scientific article published on 01 October 2019

BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study

artículo científico publicado en 2004

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma

artículo científico publicado en 2012

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

artículo científico publicado en 2016

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

artículo científico publicado en 2016

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

artículo científico publicado en 2020

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

artículo científico publicado en 2017

Biology confirmed but biomarkers elusive in melanoma immunotherapy

scientific article published on 01 April 2020

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced - or -mutated melanoma

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types

artículo científico publicado en 2013

CD40 activation as potential tool in malignant neoplasms.

artículo científico publicado en 2002

CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer

artículo científico publicado en 2019

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells

artículo científico publicado en 2017

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

article

CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type

artículo científico publicado en 2007

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

artículo científico publicado en 2016

Cancer classification using the Immunoscore: a worldwide task force

artículo científico publicado en 2012

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

artículo científico publicado en 2017

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation

artículo científico publicado en 2016

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

artículo científico publicado en 2016

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.

scientific article published on 10 August 2016

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?

artículo científico publicado en 2017

Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management

artículo científico publicado en 2020

Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group

artículo científico publicado en 2000

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

scientific article published on 20 June 2019

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies ⬇️

artículo científico publicado el 1 de octubre de 2010

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

scientific article published on 22 February 2019

Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study

artículo científico publicado en 2022

Clinical and dermoscopic criteria related to melanoma sentinel lymph node positivity

artículo científico publicado en 2007

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

artículo científico publicado en 2013

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.

artículo científico publicado en 2013

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

artículo científico publicado en 2014

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

artículo científico publicado en 2017

Clinical genetic testing for familial melanoma in Italy: A cooperative study

article

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

artículo científico publicado en 2016

Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study

scientific article published on 06 May 2020

Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care

artículo científico publicado en 2017

Combination approaches and anti-PD1 therapies: the focus of new research at ESMO and SMR

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.

artículo científico publicado en 2015

Combination therapies in advanced melanoma

article published in 2014

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters.

artículo científico publicado en 2014

Combination therapy: the next opportunity and challenge of medicine

artículo científico publicado en 2011

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

artículo científico publicado en 2015

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

artículo científico publicado en 2020

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

artículo científico publicado en 2014

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib

artículo científico publicado en 2016

Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients

artículo científico publicado en 2020

Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma

artículo científico publicado en 2011

Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial

artículo científico publicado en 2016

Computer-aided diagnosis of melanocytic lesions.

artículo científico publicado en 2005

Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment

artículo científico publicado en 2019

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

scientific article published on 04 July 2019

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients

artículo científico publicado en 2015

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients.

artículo científico publicado en 2015

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

artículo científico publicado en 2017

Corrigendum to "Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)" [Eur J Canc 137 (2020). Pages 30-39]

artículo científico publicado en 2020

Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]

artículo científico publicado en 2018

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. ⬇️

artículo científico publicado en 2018

Cosmic radiation and cancer: is there a link?

artículo científico

Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology

artículo científico publicado en 2019

Covid-19: Time for a paradigm change

artículo científico publicado en 2020

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment

artículo científico publicado en 2016

Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective

artículo científico publicado en 2020

Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study

artículo científico publicado en 2013

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

artículo científico publicado en 2012

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

artículo científico publicado en 2019

Defining the critical hurdles in cancer immunotherapy

artículo científico publicado en 2011

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma

Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay

artículo científico

Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma.

artículo científico publicado en 2013

Diagnostic services for melanoma in Italy.

artículo científico publicado en 2013

Discrepant alterations in main candidate genes among multiple primary melanomas

artículo científico publicado en 2014

Do BRAF inhibitors select for populations with different disease progression kinetics?

artículo científico publicado en 2013

EGFR mutational status in penile cancer.

artículo científico publicado en 2013

Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group.

artículo científico publicado en 2003

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

scientific article published on 15 November 2019

Editorial: Combination Strategies in the Treatment of Melanoma

artículo científico publicado en 2016

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.

artículo científico publicado en 2018

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib

artículo científico publicado en 2019

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

artículo científico publicado en 2020

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations

artículo científico publicado en 2013

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

scientific article published on 12 July 2016

Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program

scientific article published on 01 April 2020

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

artículo científico publicado en 2013

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

artículo científico publicado en 2014

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

artículo científico publicado en 2014

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

scientific article published on 04 November 2019

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg.

artículo científico publicado en 2014

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

artículo científico publicado en 2017

Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010.

artículo científico publicado en 2011

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis.

artículo científico publicado en 2017

Electrochemotherapy in melanoma patients: a single institution experience

artículo científico publicado en 2015

Emerging Strategies in Systemic Therapy for the Treatment of Melanoma

artículo científico publicado en 2018

Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations

artículo científico publicado en 2019

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

artículo científico publicado en 2018

Enzyme activity of circulating CD73 in human serum

artículo científico publicado en 2019

Epidemiological and genetic factors underlying melanoma development in Italy.

artículo científico publicado en 2015

Epiluminescence microscopy as a useful approach in the early diagnosis of cutaneous malignant melanoma.

artículo científico publicado en 1998

Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment.

artículo científico publicado en 2000

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin

artículo científico publicado en 2019

ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors

artículo científico publicado en 2015

Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

scholarly article published in Cancer Immunology, Immunotherapy

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

artículo científico publicado en 2020

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

artículo científico publicado en 2019

Evidence of publication bias in clinical trials of biotherapies for solid tumors

artículo científico publicado en 2005

Evolving impact of long-term survival results on metastatic melanoma treatment

artículo científico publicado en 2020

Expanded access programmes: patient interests versus clinical trial integrity

artículo científico publicado en 2014

Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma

artículo científico publicado en 2005

Expression of the anti-apoptotic protein BAG3 in human melanomas

artículo científico publicado en 2011

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma.

artículo científico publicado en 2018

FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy.

artículo científico publicado en 2017

Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy

artículo científico publicado en 2006

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

artículo científico publicado en 2017

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

scientific article published on 26 February 2019

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

artículo científico publicado en 2020

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

artículo científico publicado en 2019

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients

artículo científico publicado en 2020

Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?

artículo científico publicado en 2019

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. ⬇️

artículo científico publicado en 2017

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

artículo científico publicado en 2016

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

artículo científico publicado en 2013

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"

artículo científico publicado en 2011

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".

artículo científico publicado en 2012

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

artículo científico publicado en 2014

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

artículo científico publicado en 2015

Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial

artículo científico publicado en 2010

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

artículo científico publicado en 2017

Genetic alterations in main candidate genes during melanoma progression.

artículo científico publicado en 2018

Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?

artículo científico publicado en 2017

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma

scientific article published on 01 March 2019

Genomic scale analysis of NK cells impact on response to IFN-α.

artículo científico publicado en 2013

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study

artículo científico publicado en 2019

HHV-8 prevalence, immunosuppression and Kaposi's sarcoma in South Italy.

artículo científico publicado en 2001

HOTAIR role in melanoma progression and its identification in the blood of patients with advanced disease

artículo científico publicado en 2017

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).

artículo científico publicado en 2017

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma

artículo científico publicado en 2018

Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenib.

artículo científico publicado en 2019

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

artículo científico publicado en 2017

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

artículo científico publicado en 2013

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab

Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer

How do immune checkpoint targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies

artículo científico publicado en 2018

Human melanoma metastases express functional CXCR4.

artículo científico publicado en 2006

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients

artículo científico publicado en 2016

Identification of cases and estimate of direct costs of unresectable and advanced cutaneous squamous cell carcinoma: real-world data from a large Italian database

scientific article published on 23 January 2020

Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.

artículo científico publicado en 2015

Immune Checkpoint Inhibitors in Melanoma and HIV Infection

artículo científico publicado en 2017

Immuno-oncology combinations: a review of clinical experience and future prospects

artículo científico publicado en 2014

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

article

Immunological effects of BRAF+MEK inhibition

artículo científico publicado en 2018

Immunological phenotype analysis of patients with Fanconi's anaemia and their family members

artículo científico publicado en 1998

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.

artículo científico

Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients.

artículo científico publicado en 2015

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015

artículo científico publicado en 2016

Immunoscore: a new possible approach for melanoma classification

article by Mariaelena Capone et al published 2014 in Journal for Immunotherapy of Cancer

Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma

artículo científico publicado en 2014

Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts.

artículo científico publicado en 2017

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

artículo científico publicado en 2018

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management

artículo científico publicado en 2019

Immunotherapy in non-melanoma skin cancer: updates and new perspectives

Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology

artículo científico publicado en 2016

Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists

scientific article published on 01 October 2020

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

scientific article published on 16 August 2019

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

artículo científico publicado en 2020

Impact of mole mapping in the Italian health system

artículo científico publicado en 2013

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

artículo científico publicado en 2011

In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma

artículo científico publicado en 2020

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study

artículo científico publicado en 2017

Increased HOX C13 expression in metastatic melanoma progression

artículo científico publicado en 2012

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

artículo científico publicado en 2016

Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.

artículo científico publicado en 2011

Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma

artículo científico publicado en 2018

Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells

scientific article published on 11 December 2004

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy

article

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

artículo científico publicado en 2020

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

artículo científico publicado en 2020

Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?

artículo científico

Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon

artículo científico publicado en 2013

Interleukin 18: friend or foe in cancer

artículo científico

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

artículo científico publicado en 2018

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

artículo científico publicado en 2017

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

artículo científico publicado en 2012

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

artículo científico publicado en 2014

Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies

artículo científico publicado en 2013

Issues affecting molecular staging in the management of patients with melanoma

artículo científico publicado en 2007

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma

scientific article published on 01 December 2020

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma

artículo científico publicado en 2019

Lean oncology: a new model for oncologists

artículo científico publicado en 2012

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.

artículo científico publicado en 2017

Letter Regarding Editorial by Samuel Zagarella

artículo científico publicado en 2020

Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis

artículo científico publicado en 2013

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

scientific article published on 01 January 2020

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma.

artículo científico publicado en 2014

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

scientific article published on 18 September 2020

Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma.

artículo científico publicado en 2016

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

artículo científico publicado en 2013

MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness

artículo científico publicado en 2010

MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors

artículo científico

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

artículo científico publicado en 2013

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab.

artículo científico publicado en 2014

MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With Mutation Detected in Circulating-Free DNA

artículo científico publicado en 2018

Main roads to melanoma

artículo científico publicado en 2009

Management of small and intermediate congenital nevi: a nationwide survey in Italy.

artículo científico publicado en 2013

Marker utility for combination therapy

artículo científico

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Melanoma immunotherapy: strategies to overcome pharmacological resistance

scientific article published on 06 April 2020

Melanoma pathophysiology and drug targets

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

artículo científico publicado en 2020

Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy

artículo científico publicado en 2015

Melanoma: a model for testing new agents in combination therapies

artículo científico publicado en 2010

Melanoma: from research to treatment

artículo científico publicado en 2011

Melanoma: prognostic factors and factors predictive of response to therapy

scientific article published on 05 December 2019

Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition

artículo científico publicado en 2016

Melanoma: the role of surgery in the era of new therapies

artículo científico publicado en 2014

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors

artículo científico publicado en 2020

MicroRNAs in melanoma development and resistance to target therapy

artículo científico publicado en 2017

Microenvironment and tumor progression of melanoma: new therapeutic prospectives

artículo científico publicado en 2012

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials

Molecular Classification of Patients With Malignant Melanoma for New Therapeutic Strategies

Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors

artículo científico publicado en 2013

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients.

artículo científico publicado en 2013

Mucosal melanoma of the head and neck

artículo científico publicado en 2017

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

artículo científico publicado en 2020

Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets

artículo científico publicado en 2015

Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.

artículo científico publicado en 2016

Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment

artículo científico publicado en 2019

Mutation analysis of candidate genes in melanoma-prone families

article

Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach

scientific article published on 28 August 2019

Mutations in ERBB4 may have a minor role in melanoma pathogenesis

artículo científico publicado en 2013

NEMO-binding domain peptide inhibits proliferation of human melanoma cells

artículo científico publicado en 2008

NF-κB as potential target in the treatment of melanoma

artículo científico publicado en 2012

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug

artículo científico publicado en 2012

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

scientific article published on 01 July 2019

Neoadjuvant therapy in melanoma: the next step?

artículo científico publicado en 2018

Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report

artículo científico publicado en 2012

Nevoid melanoma of the vagina: report of one case diagnosed on thin layer cytological preparations

artículo científico publicado en 2007

New paradigm for stage III melanoma: from surgery to adjuvant treatment

scientific article published on 14 August 2019

Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer

artículo científico publicado en 2012

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

artículo científico publicado en 2019

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

scientific article published on 17 October 2019

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

artículo científico publicado en 2016

Nivolumab for the treatment of small cell lung cancer

scientific article published on 29 October 2019

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

article

Nivolumab in previously untreated melanoma without BRAF mutation

artículo científico publicado en 2015

Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study

scientific article published on 01 June 2017

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

artículo científico publicado en 2015

No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study

artículo científico publicado en 2020

Novel approaches in melanoma prevention and therapy

artículo científico

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway

artículo científico publicado en 2015

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

artículo científico publicado en 2017

Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

artículo científico publicado en 2020

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

artículo científico publicado en 2017

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

scientific article published on 01 June 2020

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

artículo científico publicado en 2018

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials.

artículo científico publicado en 2014

PD-1 Blockade in Anaplastic Thyroid Carcinoma

artículo científico publicado en 2020

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

scientific article published on 07 December 2020

PD-L1 expression as a potential predictive biomarker

artículo científico publicado en 2015

PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab

artículo científico publicado en 2018

PD-L1 inhibitors in the pipeline: Promise and progress.

artículo científico publicado en 2017

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies

artículo científico publicado en 2005

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

artículo científico publicado en 2015

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

artículo científico publicado en 2017

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

artículo científico publicado en 2011

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)

scientific article published on 29 November 2019

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.

artículo científico publicado en 2017

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

artículo científico publicado en 2018

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015.

artículo científico publicado en 2016

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)

artículo científico publicado en 2018

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)

artículo científico publicado en 2020

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)

artículo científico publicado en 2019

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.

artículo científico publicado en 2015

Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma

artículo científico publicado en 2010

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

artículo científico publicado en 2013

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

artículo científico publicado en 2013

Phenotype characterization of human melanoma cells resistant to dabrafenib

artículo científico publicado en 2017

Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression

Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis

scientific article published on 25 June 2019

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

scientific article published on 11 June 2019

Prognostic value of CD40 in adult soft tissue sarcomas.

artículo científico publicado en 2004

Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction

artículo científico publicado en 2003

Prognostic value of serum VEGF in melanoma patients: a pilot study

artículo científico publicado en 2004

Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials.

artículo científico publicado en 2016

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

artículo científico publicado en 2016

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab ⬇️

artículo científico publicado en 2016

Prospective clinical trials of biotherapies in solid tumors: a 5-year survey

artículo científico publicado en 2005

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

artículo científico publicado en 2019

Quality assurance in melanoma care: The EU-MELACARE study

artículo científico publicado en 2018

Ran signaling in melanoma: implications for the development of alternative therapeutic strategies

artículo científico publicado en 2014

Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS

artículo científico publicado en 2020

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review

artículo científico publicado en 2020

Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

artículo científico publicado en 2021

Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab

artículo científico publicado en 2017

Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma

scientific article published on 12 February 2019

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

artículo científico publicado en 2018

Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment

artículo científico publicado en 2010

Report from the second MIB (Melanoma Independent Board) Conference, 27-28 October 2014

artículo científico publicado en 2015

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma

scientific article published on 25 September 2018

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

artículo científico publicado en 2016

Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization

scientific article published on 15 September 2020

Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy

artículo científico publicado en 2009

Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls

artículo científico publicado en 2009

SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression

artículo científico publicado en 2014

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)

scientific article published on 30 September 2019

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

scientific article published on 21 August 2019

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

artículo científico publicado en 2014

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ⬇️

artículo científico publicado en 2016

Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy

artículo científico publicado en 2018

Selecting immuno-oncology-based drug combinations - what should we be considering?

artículo científico publicado en 2018

Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. The Melanoma Cooperative Study

artículo científico publicado en 2000

Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters

artículo científico publicado en 2004

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

artículo científico publicado en 2012

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program

artículo científico publicado en 2014

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP).

artículo científico publicado en 2013

Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma

artículo científico publicado en 2006

Serious haematological toxicity during and after ipilimumab treatment: a case series.

artículo científico publicado en 2014

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

scientific article published on 01 December 2020

Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma.

artículo científico publicado en 2017

Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009.

artículo científico publicado en 2010

Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature

scientific article published on 14 September 2020

Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.

artículo científico publicado en 2018

Side effects and toxicities of targeted therapies in stage IV melanoma

artículo científico

Single versus combination immunotherapy drug treatment in melanoma

artículo científico publicado en 2015

Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008.

artículo científico publicado en 2009

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

artículo científico publicado en 2017

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

article

Soluble interleukin-2 receptor in stage I–III melanoma

scientific article published on 01 February 2006

Starting the Fight in the Tumor: Expert Recommendations for the Development of Human Intratumoral Immunotherapy (HIT-IT)

artículo científico publicado en 2018

Sun exposure and melanoma prognostic factors

artículo científico publicado en 2016

Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors

artículo científico publicado en 2013

Surgical management of suspicious melanocytic lesions in Italy

artículo científico publicado en 2013

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

artículo científico publicado en 2014

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

scientific article published on 01 February 2019

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

scientific article published on 13 March 2020

Survival of patients with advanced metastatic melanoma: The impact of novel therapies

artículo científico

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

artículo científico publicado en 2017

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

scientific article published on 03 September 2019

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma

artículo científico publicado en 2016

Systemic Therapy for Melanoma: ASCO Guideline

scientific article published on 31 March 2020

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

artículo científico publicado en 2020

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification ⬇️

artículo científico publicado en 2013

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification.

artículo científico publicado en 2014

TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol

artículo científico publicado en 2020

Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications

artículo científico publicado en 2008

Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.

artículo científico publicado en 2017

Temozolomide and cisplatin in avdanced malignant melanoma.

artículo científico publicado en 2005

Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012.

artículo científico publicado en 2013

The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer.

artículo científico publicado en 2016

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy

artículo científico publicado en 2020

The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019

artículo científico publicado en 2020

The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.

artículo científico publicado en 2018

The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019

artículo científico publicado en 2020

The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward.

artículo científico publicado en 2008

The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era

artículo científico publicado en 2019

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

scientific article published on 01 May 2020

The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg

artículo científico publicado en 2013

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment

artículo científico publicado en 2013

The clinical and translational research activities at the INT - IRCCS "Fondazione Pascale" cancer center (Naples, Italy) during the COVID-19 pandemic

scientific article published on 23 November 2020

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions

scientific article published on 26 August 2020

The cost of unresectable stage III or stage IV melanoma in Italy

artículo científico publicado en 2012

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018

scientific article published on 15 August 2019

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.

artículo científico publicado en 2019

The immune score as a new possible approach for the classification of cancer

artículo científico publicado en 2012

The immune-related role of BRAF in melanoma

artículo científico publicado en 2014

The immune-related role of BRAF in melanoma

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.

artículo científico publicado en 2018

The influence of diet on anti-cancer immune responsiveness.

artículo científico publicado en 2018

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy

artículo científico publicado en 2017

The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma

scientific article published on 09 December 2018

The role of BRAF V600 mutation in melanoma

artículo científico publicado en 2012

The role of MEK inhibitors in the treatment of metastatic melanoma

artículo científico

The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014

artículo científico publicado en 2014

The role of optical radiations in skin cancer

artículo científico publicado en 2013

The role of spectrophotometry in the diagnosis of melanoma

artículo científico publicado en 2010

The use of interferon in melanoma patients: a systematic review

artículo científico publicado en 2014

Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)

artículo científico publicado en 2020

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

artículo científico publicado en 2020

Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report

artículo científico publicado en 2014

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

artículo científico publicado en 2019

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

artículo científico publicado en 2014

Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi

artículo científico publicado en 2016

Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study).

artículo científico publicado en 2012

Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?

artículo científico publicado en 2021

Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma

artículo científico publicado en 2020

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

article

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

scientific article published on 01 February 2019

Tumor biobanks in translational medicine

artículo científico publicado en 2012

UV exposure and melanoma prognostic factors : results from Clinical National Melanoma Registry (CNMR).

artículo científico publicado en 2014

Unexpected distribution of cKIT and BRAF mutations among southern Italian patients with sinonasal melanoma

artículo científico publicado en 2013

Update on PEG-interferon α-2b as adjuvant therapy in melanoma

artículo científico

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma

scientific article published on 02 January 2020

Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from 'Immunotherapy Bridge'

scientific article published on 01 February 2020

Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma

artículo científico publicado en 2012

Using Twitter in oncology. Research, continuing education, and advocacy

artículo científico publicado en 2015

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients

Vemurafenib beyond progression in a patient with metastatic melanoma: a case report

artículo científico publicado en 2015

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.

artículo científico publicado en 2015

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

artículo científico publicado en 2014

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

artículo científico publicado en 2017

Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial.

artículo científico publicado en 2015

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial

artículo científico publicado en 2015

Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice

artículo científico

What have we learned from cancer immunotherapy in the last 3 years?

artículo científico publicado en 2014

What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO).

artículo científico publicado en 2016

What is changing in the adjuvant treatment of melanoma?

artículo científico publicado en 2017

What's new in melanoma? Combination!

artículo científico publicado en 2015

When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report

artículo científico publicado en 2020

Who benefits most from adjuvant interferon treatment for melanoma?

artículo científico publicado en 2015

World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016

artículo científico publicado en 2017

[Cutaneous squamous cell carcinoma: immunotherapy for locally advanced and metastatic disease]

scientific article published on 01 July 2020

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

article published in 2015

miR-579-3p controls melanoma progression and resistance to target therapy

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda